Evidence map›Paper›PMID 42131756›Full record

ArticleNeuro-oncology practice2026

Neuropsychological late effects in young children with medulloblastoma: A longitudinal analysis after 5 and 15 years from the HIT-SKK-'87/'92 studies.

Holger Ottensmeier, Matthias Eyrich, René Schmidt, Paul-Gerhardt Schlegel, Bernhard Zimolong, Stefanie Frahsek, Andreas Faldum, Martin Mynarek, Lisa Bußenius, Katja Von Hoff and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Holger OttensmeierDepartment of Pediatrics, Pediatric Hematology and Oncology, University Hospital Würzburg, Würzburg, Germany (H.O., M.E., P.-G.S., S.F., Jo.K).
Matthias EyrichDepartment of Pediatrics, Pediatric Hematology and Oncology, University Hospital Würzburg, Würzburg, Germany (H.O., M.E., P.-G.S., S.F., Jo.K).ORCID https://orcid.org/0000-0002-8099-5903
René SchmidtInstitute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (R.S., A.F.).
Paul-Gerhardt SchlegelDepartment of Pediatrics, Pediatric Hematology and Oncology, University Hospital Würzburg, Würzburg, Germany (H.O., M.E., P.-G.S., S.F., Jo.K).
Bernhard ZimolongDepartment of Psychology, Ruhr-University-Bochum, Bochum, Germany (B.Z.).
Stefanie FrahsekDepartment of Pediatrics, Pediatric Hematology and Oncology, University Hospital Würzburg, Würzburg, Germany (H.O., M.E., P.-G.S., S.F., Jo.K).
Andreas FaldumInstitute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (R.S., A.F.).
Martin MynarekDepartment of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.M., L.B., K.V.H., S.R.).ORCID https://orcid.org/0000-0003-3302-2719
Lisa BußeniusDepartment of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.M., L.B., K.V.H., S.R.).ORCID https://orcid.org/0000-0003-3888-1360
Katja Von HoffDepartment of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.M., L.B., K.V.H., S.R.).
Johannes E WolffDepartment of Pediatric Oncology, University of Regensburg, Regensburg, Germany (J.E.W.).
Monika Warmuth-MetzDepartment of Neuroradiolgy, University Hospital Würzburg, Würzburg, Germany (M.W.-M.).ORCID https://orcid.org/0000-0002-3544-319X
Jürgen KraussDepartment of Pediatrics, Pediatric Hematology and Oncology, University Hospital Würzburg, Würzburg, Germany (H.O., M.E., P.-G.S., S.F., Jo.K).
Udo BodeDepartment of Pediatric Oncology, Children's Hospital, University Hospital Bonn, Bonn, Germany (U.B.).
Rolf-Dieter KortmannDepartment of Radiation Oncology, University Medical Center of Leipzig, Leipzig, Germany (R.-D.K.).ORCID https://orcid.org/0000-0002-8952-1819
Joachim Kuehl
Stefan RutkowskiORCID https://orcid.org/0000-0002-5446-9571

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Young children with medulloblastoma (MB) are especially susceptible for tumor and treatment-related brain damage. Craniospinal irradiation (CSI) has been identified as a main risk factor for cognitive and motor dysfunction 2-5 years after diagnosis. Longitudinal follow-up data on these children beyond 10 years after diagnosis are scarce. Methods: To characterize their long-term neurocognitive outcome, we analyzed a cohort of 24 MB patients below the age of 3 years at diagnosis treated within the HIT-SKK'87 (systemic chemotherapy and deferred CSI) and HIT-SKK'92 (systemic chemotherapy and intraventricular methotrexate (MTX Results: Overall, MB survivors showed subnormal test results independent of treatment, especially in the domain of motor function. CSI had an additional detrimental effect on general and fluid intelligence and simultaneous processing, whereas MTX Conclusion: Impairment of motor and cognitive skills represents a major handicap for MB survivors. Long-term development of fluid intelligence and visuomotor integration is hindered in all children. CSI further aggravated these dysfunctions. Visual or auditory domains and memory performance are less affected. Long-term neurocognitive support is warranted in young pediatric survivors of MB.

Indexed as

brain tumorcraniospinal irradiationmedulloblastomamethotrexateneurocognitive outcome

Identifiers

PMID42131756
PMCPMC13161898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.